Hypertrophic Cardiomyopathy (HCM): Hypertrophic Cardiomyopathy (HCM) is a condition of heart muscle in which the muscle is thickened (hypertrophic). This change may cause changes in the electrical signals traveling through the lower chambers of the heart and lead to ventricular arrhythmias (abnormal heart rhythm). Hypertrophic cardiomyopathy (HCM) is an autosomally transmitted cardiomyopathy with an estimated gene prevalence of 1:500, and an important cause of sudden cardiac death. In general, one half of all offspring of a known HCM patient inherit the gene, although when and how the disease manifests itself is highly variable. Screening to identify first degree relatives at risk is therefore recommended.
Hypertrophic cardiomyopathy Programme consists of:
Hypertrophic cardiomyopathy Registry and Research Data Base – a valuable tool for improving the screening and timely management of patients with Hypertrophic cardiomyopathy
‘Cardio-genetic Service’ HCM Cardio-genetic service is dedicated to helping patients and families coordinate the best care available, and strives to forge a committed, caring, lifelong relationship with each patient. To map the course of patients with suspected HCM referred to our cardiology clinic, following phenotype confirmation, a family tree and contact details from the index case will be recorded by the cardio-genetic expert team. The index case will be given literature to pass onto at risk relatives. The information pack included an open invitation (referral via primary care) to attend for screening. All blood relatives will be evaluated by genetic testing or echocardiogram— the latter at routine intervals regardless of initial results throughout, strict adherence to patient confidentiality will be maintained. Proactive screening for HCM can be effectively facilitated by cardio-genetic team services. Each new index case generates few at risk relatives who require long-term surveillance that guarantees better care.
Patient treatment and education that guarantees increased awareness as HCM is an inherited disease, and it is not enough to simply treat the patient— and all children need to be evaluated by pediatric cardiologists specializing in the disease.